EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Min Seo Kang iD, Jin Yang Baek iD, Jae-Hoon Ko iD, Sun Young Cho iD, Keon Young Lee iD, Young Ho Lee iD, Jinyoung Yang iD, Tae Yeul Kim iD, Hee Jae Huh iD, Nam Yong Lee iD, Kyungmin Huh iD, Cheol-In Kang iD und 2 weitere

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.00344-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Min Seo Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Drug Combinations, Microbial Sensitivity Tests. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated. From January 2020 to June 2023, Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales were collected. With a broth microdilution test of new BL/BLIs, cross-activity test with nine combinations of BLs and new BLIs and dose-escalation titration test for non-susceptible isolates were conducted to investigate inhibitory activities of new BLIs. A total of 188 isolates was collected and most isolates (186/188, 98.9%) carried the KPC-2 gene exclusively, while two isolates (1.1%) co-harbored NDM-1. Among the 186 KPC-2-producing isolates, 184 (98.9%) were susceptible to ceftazidime-avibactam, 173 (93.0%) to imipenem-relebactam, and 184 (98.9%) to meropenem-vaborbactam. All isolates non-susceptible to imipenem-relebactam or meropenem-vaborbactam became susceptible when avibactam replaced relebactam or vaborbactam, with 7 of 11 (63.6%) imipenem-relebactam non-susceptible isolates and both (100.0%) of the meropenem-vaborbactam non-susceptible isolates. When the minimum inhibitory concentrations (MICs) of BLs were compared using log 2 scales, combinations with avibactam showed statistically significant efficacy in lowering MICs compared to relebactam and vaborbactam (all P < 0.05). In the dose-escalation test of new BLIs, increasing dose of all new BLIs corresponded to increased susceptibility to BLs. Ceftazidime-avibactam exhibited excellent susceptibility against KPC-2-producing Enterobacterales unless co-harboring metallo-β-lactamase. The cross-combination test against non-susceptible isolates suggests that the inhibitory activity of avibactam was superior to those of relebactam or vaborbactam. Increasing the dose of new BLIs produced increased susceptibility to BLs, suggesting that high-concentration regimen need to be developed. IMPORTANCE This study investigated 188 Klebsiella pneumoniae carbapenemase (KPC)-2-producing Enterobacterales collected from January 2020 to June 2023 in a tertiary care hospital of Korea. Most isolates were susceptible to ceftazidime-avibactam (98.9%) and meropenem-vaborbactam (98.9%), while susceptibility to imipenem-relebactam was lower (93.0%). The cross-combination test using nine combinations of the individual β-lactams (BLs) and new β-lactamase inhibitors (BLIs) showed that the inhibitory activity of avibactam was significantly superior to relebactam or vaborbactam when the Log 2 MIC of BLs were compared for each combination with BLIs (all P < 0.05). The dose-escalation test of new BLIs demonstrated that increasing doses of new BLIs corresponded to increased susceptibility to BLs. Taken together, this study illustrates the excellent activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales and suggests further investigation into high-concentration regimens for potentially non-susceptible clinical isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsDrug CombinationsMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactamase InhibitorsKlebsiella pneumoniaeBacterial ProteinsBoronic AcidsHumansEnterobacteriaceae

Stichwörter der Autor:innen

KPCavibactamrelebactamsusceptibilityvaborbactam

Substanzen

CeftazidimeAzabicyclo CompoundsDrug Combinationsavibactam, ceftazidime drug combinationAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactamase InhibitorsBacterial ProteinsrelebactamBoronic Acids

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea.
  • Centre for Infection Prevention and Control, Samsung Medical Center, Seoul, South Korea.
  • Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

ORCID-Profile: Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Kang, M. S., Baek, J. Y., Ko, J. H., Cho, S. Y., Lee, K. Y., Lee, Y. H., Yang, J., Kim, T. Y., Huh, H. J., Lee, N. Y., Huh, K., Kang, C. I., Chung, D. R., & Peck, K. R. (2024). Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00344-24

Vancouver

Kang MS, Baek JY, Ko JH, Cho SY, Lee KY, Lee YH, et al. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00344-24

BibTeX
@article{Kang2024,
  author = {Kang, Min Seo and Baek, Jin Yang and Ko, Jae-Hoon and Cho, Sun Young and Lee, Keon Young and Lee, Young Ho and Yang, Jinyoung and Kim, Tae Yeul and Huh, Hee Jae and Lee, Nam Yong and Huh, Kyungmin and Kang, Cheol-In and Chung, Doo Ryeon and Peck, Kyong Ran},
  title = {Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.00344-24}
}
Kostenlos starten →